What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
Petrini P. Petrini P.
. Delahoy MJ, et al. MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1255-1260. doi: 10.15585/mmwr.mm7036e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34499627
.
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")